MRI-based Muscle Assessment for Liver Transplant Candidates
This study is looking at how muscle health, specifically using a Muscle Assessment Score (MAsS) from an MRI scan, might be linked to problems and survival rates in people with end-stage liver disease who are waiting for a liver transplant. The study will add MAsS to a standard MRI scan you would already be getting. Researchers want to see if this score can predict adverse outcomes (unwanted medical events) and mortality (death) one year after the assessment. You can join if you are an adult (18 or older) with end-stage liver disease who is being evaluated for a liver transplant and are already scheduled for an MRI scan as part of that evaluation. The study aims to enroll 100 participants.
- Study design
- This is a pilot study that will include 100 adult participants. It is an interventional study, meaning it involves an intervention (adding MAsS to an MRI).
- What's involved
- You would undergo a standard MRI scan, which will also include the Muscle Assessment Score (MAsS). The study will then track your adverse outcomes for one year.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for adverse outcomes for one year after the muscle assessment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Adverse Outcomes and Mortality in Liver Transplant
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Elizabet Carey, MD · PRINCIPAL_INVESTIGATOR · Mayo Cinic
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Muscle assessment score (MAsS)1 year
The MAsS is a composite score of muscle fat index (% of muscle fat normalized to sex, weight in kg and height in meters) and muscle volume index (muscle volume in liters normalized to patient sex, height in meters and weight in kg)
- Adverse outcomes1 year
Number of pre- and post-transplant inpatient days
- Adverse outcomes1 year
Number of pre- and post-transplant ICU days
- Adverse outcomes1 year
Number of days alive outside of the hospital in the first year after liver transplant
- Adverse outcomes1 year
Mortality within the first year after liver transplant
- MAsS changes while waiting for liver transplant1 year
In patients who remain on the waitlist, serial MAsS measurements (see Outcome 1) will be taken and changes over time will be assessed